In community-based radiology practice, mammography screening with 3D digital breast tomosynthesis (DBT) yielded lower recall rates, an increased overall cancer detection rate, and an increased detection rate for invasive cancer compared with 2D digital mammography (DM).
In the largest report to date, researchers at Washington Radiology Associates, PC, with offices in Washington, DC; Virginia; and Maryland, conducted a study of more than 59,000 patients. The results were striking: an increase in the detection rate for cancer overall of 28.6% and a 43.8% increase in detecting invasive cancers in patients screened with 3D DBT versus 2D DM.
"We observed a significant increase in the detection rate for cancer overall and an even greater increase in the detection rate for invasive cancer," said Julianne Greenberg, corresponding author of the study. "Our results may be a bellwether for the impact of tomosynthesis on population-based breast cancer screening."
American Journal of Roentgenology
The study appears ahead of print online in the .
Original report: http://bit.ly/UbH9Dx
Source: MedicalXpress
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Texas Oncology to Roll Out Canopy for ePROs After Head-to-Head Pilot
March 18th 2025Debra Patt, MD, PhD, MBA, executive vice president of Public Policy and Strategy for Texas Oncology, said the practice received positive feedback from nurses and patients during a pilot that concluded in February.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen